Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

41.7%

5 terminated/withdrawn out of 12 trials

Success Rate

28.6%

-57.9% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results4 withdrawn

Enrollment Performance

Analytics

Phase 2
6(60.0%)
Phase 1
4(40.0%)
10Total
Phase 2(6)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT03017547Phase 2Withdrawn

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Role: lead

NCT03875560Phase 2Withdrawn

IC14 in Adult Patients With Dengue Fever

Role: lead

NCT03508453Phase 2Withdrawn

IC14 for Treatment of Amyotrophic Lateral Sclerosis

Role: lead

NCT03474263Phase 2Withdrawn

IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT06275893Phase 1Completed

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Role: lead

NCT06678074Phase 1Active Not Recruiting

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Role: lead

NCT06556810Phase 1Active Not Recruiting

IC14 for Treatment of Acute Decompensated Heart Failure

Role: lead

NCT06513949Phase 2Recruiting

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

Role: lead

NCT03487263Phase 1Completed

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Role: lead

NCT04309604Unknown

IC14 for ALS Patients Expanded Access

Role: lead

NCT04391309Phase 2Terminated

COVID-19 and Anti-CD14 Treatment Trial

Role: collaborator

NCT04346277Unknown

Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

Role: lead

All 12 trials loaded